Taken together, these results suggest that in immunologically cold tumors, Compound 182 may elicit synergistic effects on anti-tumor immunity by targeting PTP1B/PTPN2 both in tumor cells and T cells. This evidence concerns the gene PTPN1 and neoplasm.